Ghosh Discusses Liso-cel Approval in Second-line LBCL
Nilanjan Ghosh, MD, PhD, discusses the expanded access second-line lisocabtagene maraleucel affords patients with large B-cell lymphoma.
Secondline Maintenance PARP Inhibition in Ovarian Cancer: Pros and Cons
“Second-line maintenance therapy is going to be incredibly important for patients because we know that once a patient with ovarian cancer recurs, their disease is incurable."
Improving Outcomes for Patients Experiencing Financial Toxicity
Financial toxicity has been linked to increased mortality rates, but can be improved with financial intervention for patients.
Consider These 3 Things Before Determining Myeloma Treatment
Clinicians should consider patient-related factors, disease-related factors, and prior therapies before deciding on a treatment regimen for patients with relapsed/refractory myeloma.
Personalized Medicine Is the New Frontier in Ovarian Cancer
Molecular testing has led to monumental strides in the field of ovarian cancer, offering women with the disease more personalized treatment options.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512